Advertisement

Kinins IV pp 127-135 | Cite as

Monoclonal Antibodies to Rat Plasma Kininogen

  • Gurrinder S. Bedi
  • Nathan Back
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 198A)

Summary

Spleen cells from Balb/c mice immunized with purified rat plasma kininogen were fused to P-3 mouse myeloma cells. Positive clones were identified by enzyme linked immunosorbent assay (ELISA), cloned successively two times with limiting dilution and expanded as ascites tumors. Five hybridomas were developed that produced monoclonal antibodies against plasma kininogen. Two of the secreted antibodies were of the IgG1(k) isotype and the remaining three were of the IgG1(λ), IgG2A(k) and IgM(k) isotypes respectively. The specificity of the monoclonal antibodies was confirmed by the immunoprecipitation of kininogen with the antibodies coupled to Sepharose-4B followed by SDS-polyacrylamide gel electrophoresis. These monoclonal antibodies recognize at least two distinct epitopes on rat plasma kininogen.

Keywords

Ascites Fluid Mouse Myeloma Cell Antibody Pair Distinct Epitope Antimouse Immunoglobulin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    H. Z. Movat, in: “Brady-kinin, Kallidin and Kallikrein,” E. G. Erdos, ed., Springer-Verlag, New York (1979).Google Scholar
  2. 2.
    G. S. Bedi, J. Balwierczak, and N. Back, Biochem. Pharmac., 32: 2061–2069 (1983).CrossRefGoogle Scholar
  3. 3.
    J. Balwierczak, G. S. Bedi, and N. Back, Adv. Expt. Med, and Biol., 156B: 727–740 (1983).Google Scholar
  4. 4.
    H. C. Li and N. Back, Prep. Biochem., 561–579 (1980).Google Scholar
  5. 5.
    N. Back and R. Steger, in: “Bradykinin and Related Peptides,” F. Sicuteri, M. Rocha E Silva, and N. Back, eds., Plenum Press, New York (1970).Google Scholar
  6. 6.
    N. Back and R. Steger, in: Vasopeptides: Chemistry, Pharmacology and Pathophysiology, N. Back and F. Sicuteri, eds., Plenum Press, New York (1972).Google Scholar
  7. 7.
    P. P. LeBlanc and N. Back, J. Natl. Cancer Inst., 54: 1107–1114 (1975).PubMedGoogle Scholar
  8. 8.
    H. C. Li, W. F. McLimans, and N. Back, Biochem. Pharmac., 26: 1187–1195 (1975).Google Scholar
  9. 9.
    G. S. Bedi, J. Balwierczak, and N. Back, Biochem. Pharmac., 32: 2071–2077 (1983).CrossRefGoogle Scholar
  10. 10.
    G. S. Bedi, J. Balwierczak, and N. Back, Adv. Expt. Med, and Biol., 156B: 705–726 (1983).Google Scholar
  11. 11.
    G. S. Bedi, J. Balwierczak, and N. Back, Biochem. Biophys. Res. Commun., 112: 621–628 (1983).PubMedCrossRefGoogle Scholar
  12. 12.
    H. Okamoto and L. M. Greenbaum, Biochem. Biophys. Res. Commun., 112: 701–708 (1983).PubMedCrossRefGoogle Scholar
  13. 13.
    R. H. Kennett, T. J. McKearn, and K. B. Bechtol, in: “Monoclonal Antibodies and Hybridomas: A New Dimension in Biological Analysis,” Plenum Press, New York (1980).Google Scholar
  14. 14.
    G. S. Bedi and N. Back, Hybridoma, 3: 287–292 (1984).PubMedCrossRefGoogle Scholar
  15. 15.
    E. Engvall, in: Methods in Enzymology, H. V. Vanakis and J. J. Langone, eds., Vol. 7OA, Academic Press, New York (1980).Google Scholar
  16. 16.
    W. M. Hunter and F. C. Greenwood, Nature, 194: 495–496 (1962).PubMedCrossRefGoogle Scholar
  17. 17.
    G. Scatchard, Ann. N. Y. Acad. Sci., 51: 660–672 (1949).CrossRefGoogle Scholar
  18. 18.
    B. Firguet, L. Djavadi-Ohaniance, J. Pages, A. Bussard, and M. Goldberg, J. Immunol. Meth., 60: 351–358 (1983).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • Gurrinder S. Bedi
    • 1
  • Nathan Back
    • 1
  1. 1.Department of Biochemical PharmacologyState University of New York at BuffaloBuffaloUSA

Personalised recommendations